ACE Inhibitor Offers Best Kidney Protection for African-Americans

| Mar 1, 2003

A recent study comparing three classes of blood pressure medications found that an ACE inhibitor did the best job of slowing kidney disease in African-Americans.

The study was the largest clinical trial ever conducted among African-Americans with kidney disease, involving 1,094 adult subjects at 21 centers for up to 6.4 years.

Participants in the African American Study of Kidney Disease and Hypertension (AASK) took either the ACE inhibitor Altace (ramipril), the dihydropyridine calcium channel blocker Norvasc (amlodipine) or the beta blocker Toprol XL (metoprolol).

Altace reduced the risk of reaching the clinical end-points of kidney failure by 22 percent compared to Toprol and by 38 percent compared to Norvasc.

Although the study ended in September 2001, the use of Norvasc in this study was halted a year earlier after results showed that the ACE inhibitor slowed kidney disease by 36 percent and reduced the risk of kidney failure and death by 48 percent in subjects who had at least 1 gram of protein in the urine.

"We were surprised that a very low blood pressure level didn't have more of an effect on the kidney," said co-author Dr. Lawrence Agodoa, who specializes in kidney diseases at the National Institutes of Health. Researchers compared a blood pressure goal of 140/90 in 554 subjects against a lower goal of 125/75 in 540 subjects.

Journal of the American Medical Association, November 20, 2002

Click Here To View Or Post Comments

Categories: Kidney Care (Nephropathy)

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.